These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36884075)

  • 1. Utilizing therapeutic drug monitoring to optimize therapy with eculizumab and mycophenolate mofetil in a child with C3 glomerulonephritis.
    Riedl Khursigara M; Chung E; Tjon J; Noone D; Chami R; Licht C; Teoh CW
    Pediatr Nephrol; 2023 Oct; 38(10):3483-3487. PubMed ID: 36884075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.
    Avasare RS; Canetta PA; Bomback AS; Marasa M; Caliskan Y; Ozluk Y; Li Y; Gharavi AG; Appel GB
    Clin J Am Soc Nephrol; 2018 Mar; 13(3):406-413. PubMed ID: 29326307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of C3 glomerulonephritis successfully treated with eculizumab.
    Payette A; Patey N; Dragon-Durey MA; Frémeaux-Bacchi V; Le Deist F; Lapeyraque AL
    Pediatr Nephrol; 2015 Jun; 30(6):1033-7. PubMed ID: 25796589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
    Fernandez-Ruiz R; Blank RB; Wu M; Belmont HM
    Lupus; 2021 Sep; 30(10):1671-1678. PubMed ID: 34192954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy.
    Balestra E; Barbi E; Ceconi V; Di Maso V; Conversano E; Pennesi M
    Pediatr Nephrol; 2024 Jan; 39(1):309-314. PubMed ID: 37493956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-Schönlein Purpura Nephritis.
    Lu Z; Song J; Mao J; Xia Y; Wang C
    Med Sci Monit; 2017 May; 23():2333-2339. PubMed ID: 28515415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.
    Caravaca-Fontán F; Díaz-Encarnación MM; Lucientes L; Cavero T; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez A; Pérez de José A; Rabasco C; Rodado R; Fernández L; Pérez Gómez V; Ávila AI; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Rodríguez E; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; Cano-Megías M; González F; Shabaka A; López-Rubio ME; Fenollosa MÁ; Martín-Penagos L; Da Silva I; Alonso Titos J; Rodríguez de Córdoba S; Goicoechea de Jorge E; Praga M;
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1287-1298. PubMed ID: 32816888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters.
    Sobiak J; Resztak M; Ostalska-Nowicka D; Zachwieja J; Gąsiorowska K; Piechanowska W; Chrzanowska M
    Eur J Pharm Sci; 2015 Sep; 77():189-96. PubMed ID: 26102431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.
    Häffner K; Michelfelder S; Pohl M
    Pediatr Nephrol; 2015 Nov; 30(11):1951-9. PubMed ID: 25986912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy.
    Kerns E; Rozansky D; Troxell ML
    Pediatr Nephrol; 2013 Nov; 28(11):2227-31. PubMed ID: 23892798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.
    Rabasco C; Cavero T; Román E; Rojas-Rivera J; Olea T; Espinosa M; Cabello V; Fernández-Juarez G; González F; Ávila A; Baltar JM; Díaz M; Alegre R; Elías S; Antón M; Frutos MA; Pobes A; Blasco M; Martín F; Bernis C; Macías M; Barroso S; de Lorenzo A; Ariceta G; López-Mendoza M; Rivas B; López-Revuelta K; Campistol JM; Mendizábal S; de Córdoba SR; Praga M;
    Kidney Int; 2015 Nov; 88(5):1153-60. PubMed ID: 26221755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome.
    Tellier S; Dallocchio A; Guigonis V; Saint-Marcoux F; Llanas B; Ichay L; Bandin F; Godron A; Morin D; Brochard K; Gandia P; Bouchet S; Marquet P; Decramer S; Harambat J
    Clin J Am Soc Nephrol; 2016 Oct; 11(10):1777-1782. PubMed ID: 27445161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
    Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M
    Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission of resistant MPGN type I with mycophenolate mofetil and steroids.
    De S; Al-Nabhani D; Thorner P; Cattran D; Piscione TD; Licht C
    Pediatr Nephrol; 2009 Mar; 24(3):597-600. PubMed ID: 18972137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation.
    Naseer MS; Singh A; Singh N
    Glomerular Dis; 2022 Apr; 2(2):100-105. PubMed ID: 36751532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab in Pediatric Dense Deposit Disease.
    Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with mycophenolate mofetil attenuates the development of Heymann nephritis.
    Luca ME; Paul LC; van Der Wal AM; Bruijn JA; de Heer E
    Exp Nephrol; 2000; 8(2):77-83. PubMed ID: 10729746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
    Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
    Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.